Prescription medicines under evaluation
These applications for new medicines or new uses for existing medicines are currently under evaluation by the TGA. Evaluation does not guarantee registration or PBS entry.
You can narrow down the results using the filters.
- Application type A: applications for a 'new medicine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia
- Application type B: applications for a 'new combination', where two or more already approved medicines are combined into a single product
- Application type C: applications for a 'new indication', or additional therapeutic use, for an already approved medicine.
For more information visit Prescription medicines: applications under evaluation.
- May-2023Prescription medicine evaluationActive ingredient: Meningococcal polysaccharide Group Y, Meningococcal polysaccharide group A, Meningococcal polysaccharide group C, Meningococcal polysaccharide group W135, Neisseria meningitidis serogroup B recombinant lipidated- factor H binding protein subfamily A, Neisseria meningitidis serogroup B recombinant lipidated- factor H binding protein subfamily B